MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · Pain physician · 2023

Pain Relief After Allogenic Stem Cell Disc Therapy.

Lewandrowski Kai-Uwe, Dowling Alvaro, Vera Juan Carlos, Leon Jorge Felipe Ramirez, Telfeian Albert E, Lorio Morgan P

Наблюдательное исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

Treatment of intermediate-stage painful degenerative disc disease is controversial, with few reliable options. Allogenic mesenchymal stem cells (MSCs)are an alternative to autologous stem cell transplantation. Allogeneic MSCs in the treatment of discogenic low back pain have some practical advantages, ranging from availability to ease of treatment in a procedure-room setting.

OBJECTIVES

To assess the efficacy and safety of allogenic MSC injection into painful lumbar intervertebral discs and associated clinical outcomes.

STUDY

DESIGN

Retrospective observational cohort study.

SETTING

Private practice.

METHODS

There were 33 patients: 15 women and 18 men with an average age of 47.6 years. The patients' average follow-up was 26.88 months Patients were treated with intradiscal injection of approximately 5 million allogeneic polyclonal MSCs in 1% hyaluronic acid derived from immunoselected umbilical cord stem cells. Patients were monitored for adverse event reactions. Clinical outcomes were assessed with reductions in the reported Visual Analog Scale (VAS) for back pain, the Oswestry Disability Index (ODI) scores, and the use of the modified Macnab criteria.

RESULTS

No patient required any additional treatments for low back pain stemming from the level treated with MSC injections. At a 2-year follow-up, the average VAS low back score reduction was 6.565 ± 1.619 and 38.333 ± 14.865 for the ODI (P < 0.001). Reported Macnab outcomes were excellent in 11 patients (33.3%), good in 19 (57.6%), and fair in 3 (9.1%).

LIMITATIONS: Our observational study is limited by patient selection, hindsight bias, and low patient numbers.

CONCLUSION

The results of our feasibility study suggest that the injection of allogeneic MSCs to treat patients with painful intermediate-stage degenerative disc disease has merit. No adverse reactions were observed. The authors recommend further study in a randomized prospective study setting with a placebo control group or a natural history study group of patients to solidify this research.

Для цитирования: Lewandrowski Kai-Uwe, Dowling Alvaro, Vera Juan Carlos, Leon Jorge Felipe Ramirez, Telfeian Albert E, Lorio Morgan P. Pain Relief After Allogenic Stem Cell Disc Therapy.. Pain physician. 2023.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.